LSE creators

Number of items: 43.
Article
  • Briggs, Andrew, Angelis, Aris, Chen, Jieling, Booth, David, Davis, Jason A., Vaduganathan, Muthiah, Jhund, Pardeep S. (2025). Composite endpoints in health technology assessment: part 1 - an illustration of best modeling practice. Journal of Comparative Effectiveness Research, 14(10). https://doi.org/10.57264/cer-2024-0117 picture_as_pdf
  • Kanavos, Panos, Visintin, Erica, Angelis, Aris (2024). Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines: a retrospective analysis. The Lancet Oncology, 25(12), 1644 - 1654. https://doi.org/10.1016/S1470-2045(24)00505-9 picture_as_pdf
  • Angelis, Aris, Aggarwal, Ajay, Miners, Alec, Cairns, John, Briggs, Andrew (2023). The Innovative Medicines Fund a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep? Journal of the Royal Society of Medicine, 116(10), 324 - 330. https://doi.org/10.1177/01410768231192476 picture_as_pdf
  • Angelis, Aris, Harker, Martin, Cairns, John, Seo, Mikyung Kelly, Legood, Rosa, Miners, Alec, Wiseman, Virginia, Chalkidou, Kalipso, Grieve, Richard, Briggs, Andrew (2023). The evolving nature of Health Technology Assessment: a critical appraisal of NICE’s new methods manual. Value in Health, 26(10), 1503 - 1509. https://doi.org/10.1016/j.jval.2023.05.015 picture_as_pdf
  • Angelis, Aris, Montibeller, Gilberto Neto, Kanavos, Panos (2023). A structured methodology for essential medicines lists and health emergency stockpiles: experience with the Emergency Medicines Buffer Stock in the United Kingdom. Social Science and Medicine, 337, https://doi.org/10.1016/j.socscimed.2023.116236 picture_as_pdf
  • Angelis, Aris, Polyakov, Roman, Wouters, Olivier J., Torreele, Els, McKee, Martin (2023). High drug prices are not justified by industry’s spending on research and development. BMJ, 380(8371). https://doi.org/10.1136/bmj-2022-071710 picture_as_pdf
  • Angelis, A., Mellerio, J. E., Kanavos, Panos (2022). Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Orphanet Journal of Rare Diseases, 17(1). https://doi.org/10.1186/s13023-022-02419-1 picture_as_pdf
  • Angelis, Aris, Suarez Alonso, Carlos, Kyriopoulos, Ilias, Mossialos, Elias (2022). Funding sources of therapeutic and vaccine clinical trials for COVID-19 vs non-COVID-19 indications, 2020-2021. JAMA network open, 5(8). https://doi.org/10.1001/jamanetworkopen.2022.26892 picture_as_pdf
  • Angelis, Aris, Phillips, Lawrence D. (2021). Advancing structured decision-making in drug regulation at the FDA and EMA. British Journal of Clinical Pharmacology, 87(2), 395 - 405. https://doi.org/10.1111/bcp.14425 picture_as_pdf
  • Angelis, Aris, Baltussen, Rob, Tervonen, Tommi (2021). The need for novel approaches in assessing the value of COVID-19 vaccines. American Journal of Public Health, 111(2), 205 - 208. https://doi.org/10.2105/AJPH.2020.306066
  • Angelis, Aris, Naci, Huseyin, Hackshaw, Allan (2020). Recalibrating health technology assessment methods for cell and gene therapies. PharmacoEconomics, 38(12), 1297-1308. https://doi.org/10.1007/s40273-020-00956-w picture_as_pdf
  • Angelis, Aris, Thursz, Mark, Ratziu, Vlad, O'Brien, Alistair, Serfaty, Lawrence, Canbay, Ali, Schiefke, Ingolf, Bana e Costa, João C., Lecomte, Pascal, Kanavos, Panos (2020). Early health technology assessment during nonalcoholic steatohepatitis drug development: a two-round, cross-country, multicriteria decision analysis. Medical Decision Making, 40(6), 830 - 845. https://doi.org/10.1177/0272989X20940672 picture_as_pdf
  • Angelis, Aris, Kanavos, Panos, Phillips, Lawrence D. (2020). ICER value framework 2020 update: recommendations on the aggregation of benefits and contextual considerations. Value in Health, 23(8), 1040 - 1048. https://doi.org/10.1016/j.jval.2020.04.1828 picture_as_pdf
  • Angelis, Aris, Linch, Mark, Montibeller, Gilberto, Molina Lopez, Maria Teresa, Zawada, Anna, Orzel, Kinga, Arickx, Francis, Espin, Jaime, Kanavos, Panos (2020). Multiple criteria decision analysis for HTA across four EU member states: piloting the Advance Value Framework. Social Science & Medicine, 246, https://doi.org/10.1016/j.socscimed.2019.112595 picture_as_pdf
  • Tervonen, Tommi, Angelis, Aris, Hockley, Kimberley, Pignatti, Francesco, Phillips, Lawrence D. (2019). Quantifying preference in drug benefit-risk decisions. Clinical Pharmacology and Therapeutics, 106(5), 955-959. https://doi.org/10.1002/cpt.1447 picture_as_pdf
  • Kanavos, Panos, Angelis, Aris, Drummond, Michael (2019). An EU-wide approach to HTA an irrelevant development or an opportunity not to be missed? European Journal of Health Economics, 20(3), 329-332. https://doi.org/10.1007/s10198-019-01037-2
  • Angelis, Aris, Kanavos, Panos (2018). Comment on: “Does MCDA trump CEA?”. Applied Health Economics and Health Policy, https://doi.org/10.1007/s40258-018-0445-z picture_as_pdf
  • Angelis, Aris (2018). Evaluating the benefits of new drugs in health technology assessment using multiple criteria decision analysis: a case study on metastatic prostate cancer with the dental and pharmaceuticals benefits agency (TLV) in Sweden. MDM: Policy and Practice, 3(2). https://doi.org/10.1177/2381468318796218
  • Angelis, Aris, Lange, Ansgar, Kanavos, Panos (2018). Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 19(1), 123-152. https://doi.org/10.1007/s10198-017-0871-0
  • Angelis, Aris, Montibeller, Gilberto, Hochhauser, Daniel, Kanavos, Panos (2017). Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Medical Informatics and Decision Making, 17(149). https://doi.org/10.1186/s12911-017-0524-3
  • Angelis, Aris, Kanavos, Panos (2017). Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Social Science & Medicine, 188, 137-156. https://doi.org/10.1016/j.socscimed.2017.06.024
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Pringle, Edward, Kanavos, Panos (2017). Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Retina, 37(5), 886-895. https://doi.org/10.1097/IAE.0000000000001280
  • Angelis, Aris, Tordrup, David, Kanavos, Panos (2017). Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Global Policy, 8(S2), 7-22. https://doi.org/10.1111/1758-5899.12341
  • Angelis, Aris, Kanavos, Panos, Montibeller, Gilberto (2017). Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Global Policy, 8(S2), 76-83. https://doi.org/10.1111/1758-5899.12387
  • Nicod, Elena, Jackson, Timothy L., Grimaccia, Federico, Angelis, Aris, Costen, Marc, Haynes, Richard, Hughes, Edward, Pringle, Edward, Zambarakji, Hadi, Kanavos, Panos (2016). Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. European Journal of Health Economics, 17(8), 991-999. https://doi.org/10.1007/s10198-015-0741-6
  • Angelis, Aris, Kanavos, Panos (2016). Critique of the American Society of Clinical Oncology value assessment framework for cancer treatments: putting methodologic robustness first. Journal of Clinical Oncology, 34(24), 2935-2936. https://doi.org/10.1200/JCO.2015.64.9673
  • Angelis, Aris, Kanavos, Panos (2016). Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. PharmacoEconomics, 34(5), 435-446. https://doi.org/10.1007/s40273-015-0370-z
  • Angelis, Aris, Tordrup, David, Kanavos, Panos (2015). Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Health Policy, 119(7), 964-979. https://doi.org/10.1016/j.healthpol.2014.12.016
  • Tervonen, Tommi, Naci, Huseyin, van Valkenhoef, Gert, Ades, Anthony E., Angelis, Aris, Hillege, Hans L., Postmus, Douwe (2015). Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Medical Decision Making, 35(7), 859-871. https://doi.org/10.1177/0272989X15587005
  • Kanavos, Panos, Angelis, Aris (2014). Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Pharmaceutical Medicine, online, https://doi.org/10.1007/s40290-014-0066-2
  • Tordrup, David, Angelis, Aris, Kanavos, Panos (2013). Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey. Applied Health Economics and Health Policy, 11(6), 639-652. https://doi.org/10.1007/s40258-013-0056-7
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Prevost, Andrew T., Simpson, Andrew R.H., Kanavos, Panos (2013). Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Retina, 33(10), 2012-2017. https://doi.org/10.1097/IAE.0b013e3182a6b3e2
  • Jackson, Timothy L., Nicod, Elena, Angelis, Aris, Grimaccia, Federico, Prevost, Toby, Simpson, Andrew, Kanavos, Panos (2013). Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Retina, 33(6), 1099-1108. https://doi.org/10.1097/IAE.0b013e31828991d6
  • Jackson, Timothy, Nicod, Elena, Simpson, Andrew, Angelis, Aris, Grimaccia, Federico, Kanavos, Panos (2013). Symptomatic vitreomacular adhesion. Retina, 33(8), 1503-1511. https://doi.org/10.1097/IAE.0b013e31829232fd
    • Dataset
  • Angelis, A., Kanavos, P., Mellerio, J. E. (2022). Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. [Dataset]. figshare. https://doi.org/10.6084/m9.figshare.c.6185650
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Lopes Vieira, Ana, Dimitrovová, Klára, Bana e Costa, Carlos (2021). IMPACT HTA, WP7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 2 (Multi-criteria evaluation framework), Results of the 1st Web-Delphi process to HTA stakeholders, organized into 6 separate parallel panels. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5256671
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Lopes Vieira, Ana, Bana e Costa, Carlos (2021). IMPACT HTA, WP7 (Methodological tools using multi-criteria value methods for HTA decision-making), Task 2 (Multi-criteria evaluation framework), Results of the 2nd Web-Delphi process to HTA stakeholders, organized in a single panel. [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5256844
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Bana e Costa, Carlos (2021). Results of the Web-Delphi process to INAMI stakeholders (three rounds). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5257297
  • Angelis, Aris, Kanavos, Panos, Oliveira, Mónica Duarte, Dimitrovová, Klára, Bana e Costa, Carlos (2021). Results of the Web-Delphi process to YLV stakeholders (three rounds). [Dataset]. Zenodo. https://doi.org/10.5281/zenodo.5257424
    • Thesis
  • Angelis, Aris Nikolaos (2017). Multiple criteria decision analysis for assessing the value of new medical technologies: researching, developing and applying a new value framework for the purpose of health technology assessment [Doctoral thesis]. London School of Economics and Political Science. https://doi.org/10.21953/lse.64458ag2wceo
    • Online resource
  • Angelis, Aris (2016). Why are the prices of new medicines so high and what can we do about it? (F8).
  • Angelis, Aris, Kanavos, Panos (2015). Large scale mergers and acquisitions in the pharmaceutical industry: 1 + 1 = 1?
    • Working paper
  • Kanavos, Panos, Angelis, Aris (2013). Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework. (LSE Health working papers 33). LSE Health.